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CyclooxygenaseLactoferrin (LF) is believed to contribute to the host's defense against microbial infections. This work focuses
on the antibacterial and antifungal activities of a designed peptide, L10 (WFRKQLKW) by modifying the ﬁrst
eight N-terminal residues of bovine LF by selective homologous substitution of amino acids on the basis of hy-
drophobicity, L10 has shown potent antibacterial and antifungal properties against clinically isolated extend-
ed spectrum beta lactamases (ESBL), producing gram-negative bacteria as well as Candida strains with
minimal inhibitory concentrations (MIC) ranging from 1 to 8 μg/mL and 6.5 μg/mL, respectively. The peptide
was found to be least hemolytic at a concentration of 800 μg/mL. Interaction with lipopolysaccharide (LPS)
and lipid A (LA) suggests that the peptide targets themembrane of gram-negative bacteria. Themembrane in-
teractive nature of the peptide, both antibacterial and antifungal, was further conﬁrmed by visual observations
employing electron microscopy. Further analyses, by means of propidium iodide based ﬂow cytometry, also
supported the membrane permeabilization of Candida cells. The peptide was also found to possess
anti-inﬂammatory properties, by virtue of its ability to inhibit cyclooxygenase-2 (COX-2). L10 therefore
emerges as a potential therapeutic remedial solution for infections caused by ESBL positive, gram-negative
bacteria and multidrug-resistant (MDR) fungal strains, on account of its multifunctional activities. This
study may open up new approach to develop and design novel antimicrobials.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The emergence of epidemic causing drug resistant microbes has
galvanized interest and research in the urgent task of developing pep-
tide antibiotics. In recent times, infections caused by the community
acquired extended spectrum beta lactamases (ESBL) producing
Escherichia coli, Klebsiella sp. and potential epidemic causing fungal
pathogens such as Candida albicans and Candida tropicalis have be-
come an area of major interest, especially when one considers the
threat they are likely to pose to hospitalized patients [1,2]. In an era
where there is sufﬁcient clinical evidence to indicate increasing mi-
crobial resistance to existing antibiotics, the task of developing alter-
nate therapeutics assumes critical importance.
Antimicrobial peptides (AMPs) are currently under consideration
as a potential alternative to conventional antibiotics, on account of, All India Institute of Medical
91 11 2616 3879; fax: +91 11
.
rights reserved.their widespread occurrence throughout nature [3–5]. AMPs have al-
ready distinguished themselves, being one of the most important el-
ements of the innate immune system. More than 1900 natural
AMPs are registered in the Antimicrobial Peptide Database (APD:
http://aps.unmc.edu/AP/main.html), emphasizing the importance of
expanding AMP research [6]. Moreover, logic dictates that, given
their capacity for broad spectrum activity, these molecules would
also be unlikely to pose a serious cause, if any, for the development
of antimicrobial resistance to these peptides. This is further enhanced
by their ability to swiftly destroy infection causing microbes.
Being mostly cationic in nature, they exhibit a high afﬁnity for the li-
popolysaccharide (LPS) or endotoxin layer of the gram-negative strains
that are associated with pathogenicity, a fact that is further reinforced
by the critical role they play in the lethal endotoxic shock syndrome
[7,8]. Moreover, microbial infections are known to interfere with cell sig-
nals, leading to the activation of cyclooxygenase-2 (COX-2) andphospho-
lipase A2 production — the very enzymes that trigger inﬂammation [9].
The fragments of lactoferrin (LF) are attractive candidates for phar-
maceutical applications on account of a variety of reasons. First, they
have proved to be effective within the problem scenario of accelerating
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antibacterial and antifungal peptides obtained from the N-terminal
region of human and bovine LF have been shown to be highly active;
most of them are membrane interactive [12–18]. Other possible targets
of action are mitochondria and DNA of C. albicans [15,19]. Such antimi-
crobial peptides include the ﬁrst 11 residues of N-terminal amino acids
of human LF (hLF), which are highly effective against infections caused
by multidrug-resistant (MDR) Staphylococcus aureus in rodents [20],
besides also eradicating Acinetobacter baumannii from infected patients
[12]. Secondly, the native LFmolecule also acts as an anti-inﬂammatory
factor by binding to the cell walls (LPS) of microbes and inhibiting the
production of pro-inﬂammatory factors [21].
In this study, we focused on and synthesized the ﬁrst 8 residues of
N-terminal of bovine LF with sequence APRKNVRW, other peptides
being designed from this template. Each amino acid was sequentially
substituted by its homologs with varying hydrophobicity. Here, we
have reported the antibacterial activity of modiﬁed N-terminal 8 resi-
due peptide derived from bovine LF against gram-negative strains,
the major focus being on ESBL positive E. coli, K. pneumoniae and
Acinetobacter sp. Further screening was done for antifungal activity
against clinically isolated Candida sp. related to blood stream infec-
tions, with a view to developing the best antimicrobial peptide L10
with sequence WFRKQLKW. Other in vitro properties related to
haemolytic, anti-COX-2, and mechanisms involving their action,
were also analyzed.
2. Materials and methods
2.1. Microorganisms
For antibacterial assay, clinical isolates of all ESBL positive gram-
negative bacterial strains i.e. E. coli, K. pneumoniae and Acinetobacter
sp. were isolated from sputum, urine and pus samples. E. coli (ATCC
25923) was used for quality control. The strains used for determining
candidacidal activity were C. albicans (ATCC SC5314), C. tropicalis
(ATCC 13803), C. krusei (ATCC 6258), C. glabrata (ATCC 15126) and
C. parapsilosis (ATCC 22019) and their respective clinical isolates cul-
tured from blood stream infection. All clinical isolates were obtained
from hospitalized patients of All India Institute of Medical Sciences,
New Delhi, India. Strains were properly identiﬁed by using standard
biochemical tests.
2.2. Synthesis of peptides
The peptides were synthesized by solid phase peptide synthesiz-
er PS3 (Protein technology, USA) using Fmoc and Wang resin (G.L.
Biochem, China) chemistry [22]. The solvent used for synthesis
was dimethylformamide (DMF). 2-(1H-Benzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexaﬂuorophosphate (HBTU) was used as an
activator. Fmoc was deprotected by 20% piperidine, and Wang resin
was cleaved using triﬂuoroacetic acid (TFA). The peptides were pre-
cipitated from dry ether.
2.3. Analytical RP-HPLC of peptide
The purity of the peptides (>95%) was veriﬁed by analytical
RP-HPLC using C18 reversed phase column (1.6×10 cm, Amersham
Bioscience). 1 mg/mL of peptide was loaded onto the RPC column.
The linear gradient was formed by passing two different solvents: sol-
vent A was 0.05% aqueous TFA, pH 2 and solvent B was 0.05% TFA in
acetonitrile. The ﬂow rate was 0.25 mL/min at room temperature.
2.4. Measurement of minimal inhibitory concentration (MIC)
Cationic peptides tend to stick to the walls of polystyrene microti-
ter plates. Hence, the MIC of cationic peptide was determined usingmodiﬁed microtiter broth dilution method (http://cmdr.ubc.ca/
bobh/methods/methodsall.html) in polypropylene 96 well microtiter
plates. For antibacterial assay, serial two-fold dilutions of each pep-
tide solution, along with Gentamycin as control antibiotic, were pre-
pared in (COSTAR, catalogue no. 3790) Mueller Hinton (MH) broth.
A total of 100 μL of the adjusted inoculum (5×105 CFU/mL) organ-
isms were added to each well, after which the plates were incubated
overnight at 37 °C in ambient air.
The antifungal activities of the peptides were determined by fol-
lowing the guidelines proposed by the Clinical and Laboratory Stan-
dards Institute (CLSI) (Clinical and Laboratory Standard Institute;
formerly the National Committee for Clinical Laboratory Standards
(NCCLS) [23]. Serial two-fold dilutions of peptide solutions (100 μL)
were prepared in microtiter plate. A total of 100 μL of the adjusted in-
oculum (105 CFU/mL) organisms in RPMI medium buffered at pH 7.0
with MOPS buffer were added to each well. The plates were then in-
cubated overnight at 37 °C in ambient air. Fluconazole was used as
the control antibiotic.
In both tests, organisms without peptide were treated as the pos-
itive control, while uninoculated broth was used as the negative con-
trol. The MIC was taken as the lowest drug concentration at which the
observable growth was inhibited. The results were conﬁrmed by
reading the plate in a 96 well Microplate reader (Biotech Instru-
ments). Experiments were performed in triplicate and the mean
values were interpreted.
2.5. Solubility of peptides and stability of solutions
To get an understanding of the self-degradation of the peptides
during the study period, we checked the stability of the peptide
under different conditions. Three aliquots each of 200 μL (stock solu-
tion of 640 μg/mL) of L10 were stored at room temperature, −20 °C
and 4 °C, respectively. Each aliquot was tested for antimicrobial activ-
ity after time intervals of 7, 14, 21 and 30 min [24].
2.6. Measurement of minimal hemolytic concentration (MHC)
The hemolytic effect of the peptides was determined on human
red blood cells (hRBC). The freshly collected blood was centrifuged
for 10 min to remove the buffy coat and washed with phosphate buff-
ered saline (PBS: 35 mM Na2HPO4, pH 7.0 and 150 mM NaCl). 100 μL
of the hRBC (suspended in 4% (v/v) in PBS) and 100 μL of peptide so-
lution were added into sterilized 96 well plate. The plate was then in-
cubated for 1 h at 37 °C and centrifuged at 1000 ×g for 5 min. The
supernatant in aliquots (100 μL) was transferred to fresh 96 well
plates, where the hemoglobin released was monitored spectrophoto-
metrically at 414 nm. Similar steps were carried out for Gentamycin
as control. The percentage of hemolysis was calculated by using the
following formula:
% Hemolysis ¼ f Abs414 nm in the peptide solution−Abs414 nm in PBSð Þ
= Abs414 nm in 0:1% TritonX 100−Abs414 nm in PBSð Þg
100
Zero percentage and 100% hemolysis were determined in PBS and
0.1% Triton X-100, respectively.
2.7. Calculation of therapeutic index (TI)
The value of TI refers to the property of cell selectivity of any drug
molecule. It is a measurement of the capability of distinctions be-
tween any pathogen and its host cells. The ratio of MHC to MIC
gives the value of TI. The MHC and MIC values were determined by
2-fold dilutions. There was no detectable hemolysis at 800 μg/mL of
peptide concentration, so the value of 1600 μg/mL was used to calcu-
late the TI.
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The bacterial strains were grown overnight at 37 °C in MH broth
in ambient air. Aliquots of exponentially growing bacteria were
re-suspended in fresh MH broth at an approximate density of
107 cells/mL, then separately exposed to the peptide at a ﬁnal con-
centration of two times the MIC, i.e., 2 μg/mL, for 0, 5, 10, 20, 30, 40,
60, 90, 120, and 150 min at 37 °C. After each observation, samples
were serially diluted and plated onto MH agar plates to obtain viable
colonies.
A similar procedure was carried for the fungal strains, albeit with
some modiﬁcations. The broth used was RPMI medium buffered to
pH 7.0 with MOPS buffer, and the cell density used was approximate-
ly 2×105 cells/mL. Furthermore, Sabouraud Dextrose Agar (SDA)
plates were used to obtain the viable colonies.
2.9. Electron microscopic studies
EM studies were conducted to evaluate themechanism of action of
L10. We used transmission electron microscopy (TEM) to see the in-
teraction of the peptide with a clinical isolate of the ESBL positive
E. coli. Freshly inoculated liquid cultures of the bacteria in MHB were
grown, up to mid logarithmic phase. These were washed well with
sodium phosphate buffer (10 mM) and centrifuged for 3 min at
1500 ×g. The pellet obtained was ﬁxed in 2.5% glutaraldehyde in
0.1% phosphate buffer for 3 h at 4 °C. The pellet was washed three
times with 0.1% phosphate buffer. The samples were post ﬁxed in 1%
osmium tetroxide in 0.1 Mphosphate buffer for 2 h. The ﬁxed samples
were washed with phosphate buffer followed by dehydrating with a
series of acetone gradients. These samples were passed through pro-
pylene oxide and inﬁltrated in epoxy resin for overnight. These were
embedded in pure epoxy resin and cured at 60 °C for 72 h. Ultracut
Reichert Jung-Austria microtome was used to obtain golden color sec-
tions, andwas thereafter stainedwith 2% uranyl acetate and Reynold's
lead citrate. The sections were observed under a Morgagni-268 elec-
tron microscope. Test samples were processed in the same way by
pretreating with L10 (108 cells in 100 μL were treated with 4 μg of
peptide) [25]. The samples were analyzed for different lengths of
time (5 to 30 min).
A similar study involving scanning electron microscopy (SEM) was
conducted to evaluate the antifungal mechanism of action with quality
control isolates of C. albicans (ATCC SC5314) and C. tropicalis (ATCC
13803). Similar steps as in TEMwere followed to collect the fungal pel-
let. The test samples were pretreated with L10 (hundred folds MIC) for
respective fungal strains for 2 h [15]. A high concentration of peptide
was chosen in order to achieve killing of a high number of yeast cells
(ﬁnal concentration of 2×107 cells/mL). They were ﬁxed in an alde-
hydemixture (2% paraformaldehyde, 2.5% glutaraldehyde in 0.05 M so-
dium cacodylate buffer, pH 7.2) diluted in a ratio 1:1 with PBS. The
suspension was then washed with PBS. The yeast cells (250 μL) were
transferred to poly-L-lysine treated, gold coated Thermanox™ cover-
slips for 30 min to allow the cells to adhere to the surface. After rinsing
with PBS, cells were prepared for SEMusingOTOTOmethod comprising
repeated treatment with osmium tetroxide and thiocarbohydrazide
[26]. The coverslips were dehydrated with ethanol and were inﬁltrated
with hexamethyldisilazane, and were then allowed to evaporate in a
fume hood. The dried specimens were then mounted on aluminium
SEM stubs and examined without thin ﬁlm metal coating in a scanning
electron microscope (Leo Imaging Systems).
2.10. In vitro tests supporting antibacterial activities
2.10.1. LPS-binding assay
The endotoxin binding assay was carried out by the quantitative
chromogenic LAL kit. (Genscript, USA Inc.) Stock solution of L10
(64 μg/mL) was prepared in pyrogen-free water and serially dilutedin the same solvent. Twenty-ﬁve microliter peptide solution and
25 μL of 1 U/mL of LPS were mixed in each well, and plates were in-
cubated for 30 min at 37 °C to allow the peptide to bind with LPS.
The mixture was incubated for 10 min in the presence of 50 μL of
amebocyte lysate reagent, and 100 μL of the chromogenic substrate
was added. Incubation was continued at 37 °C for 6 min and release
of the product was monitored at 545 nm using Spectrophotometer
(T 60 UV, PG instrument. The change in optical density (ΔOD) be-
tween 0 and 6 min was calculated for the control sample, which
contained the peptide with no LPS, and this value was subtracted
from the ΔOD between 0 and 6 min for samples containing both the
peptide and LPS. The percentage of LPS binding with different concen-
trations of peptide was calculated from the quotient (Q) of the ΔOD,
with peptide divided by the ΔOD of peptide-free control samples,
using the formula (1−Q)×100. Standard curves generated with in-
creasing amounts of LPS were linear between 0.1 and 1.0 endotoxin
units/assay. Colistin was used as positive control for its high binding
property to LPS.
2.10.2. Bio-interaction between L10 peptide and Lipid A (LA)
The binding of L10 with LAwas determined by surface plasmon res-
onance (SPR) [27–29] using BIAcore 2000 (Pharmacia, Sweden). HPA
chip was washed with 25 μL of 40 μM n-octyl β-D-glucopyranoside
(Sigma). LA (diphosphoryl from E. coli F583, Rd mutant) was sonicated
for 15 min at 37 °C before immobilization. 100 μL of LA (0.1 mg/mL)
was passed over washed ﬂow cell of HPA chip at a ﬂow rate of
1 μL/min for 100 min. The excessive LA was removed by 0.1 M
NaOH to obtain a monolayer of LA. Around 1063 Resonance Unit
(RU) of LA was immobilized under this condition. Three concentra-
tions of L10 (4.19, 12.58 and 20.97 μM) were passed over LA at a
ﬂow rate of 10 μL/min, and changes in sensogram were observed.
After passing each concentration of peptide, it was regenerated by
0.1 MNaOH. The graph shows the change in RU values with different
concentrations of peptides. KA and KD were obtained by ﬁtting the
primary sensogram data using the BIAevaluation 3.0 software.
The dissociation constant is derived using the equation
Rt ¼ Rtoe−kD
t−toð Þ
where Rt is the response at time t, Rto is the amplitudes of the initial
response and KD is the dissociation constant. The association constant
KA can be derived using equation given below from the measured KD
values.
Rt ¼ Rmax 1−e− KACþKDð Þ t−t0ð Þ
 
where Rt is the response at time t, Rmax is the maximum response, and
C is the concentration of the analyte in the solution. KA and KD are the
association and dissociation constants respectively.
2.11. In vitro tests supporting antifungal activities
2.11.1. Candida membrane permeability
The permeabilization of the Candida sp. membrane was investigat-
ed by ﬂow cytometric analysis by the DNA binding ﬂuorescent probe
propidium iodide (PI), as described previously [15]. Brieﬂy, yeast cells
were grown overnight and were transferred to fresh RPMI medium
buffered to pH 7.0 with MOPS buffer for another 2 h of growth.
Cells were washed and diluted in 10 mM phosphate buffer (pH 7.2).
Yeast cells were exposed to the peptides at different concentrations
(1, 10, 100 and 1000 μg/mL) and incubated for 2 h at 37 °C. The
ﬁnal density of the yeast cells was 2×106 cells/mL. The cells were
then re-incubated at room temperature with 1 μg of PI for 5 min,
followed by analysis on a FACScan Flow Cytometer.
Table 1
Primary screening of the peptides by the determination of MIC against standard strain
of E. coli (ATCC- 25923). Gentamycin was used as control antibiotic.
Peptide Sequence MIC (μM) MIC (μg mL−1)
L1 APRKNVRW 62.36 64
L2 APRKNVRF 129.66 128
L3 APRKNVKW 64.11 64
L4 APRKNLKW 31.61 32
L5 APRKQLKW 7.79 8
L6 APRRQLKW 15.17 16
L7 APKKQLKW 16.02 16
L8 AFRKQLKW 3.71 4
L9 LFRKQLKW 1.78 2
L10 WFRKQLKW 0.8 1
Gantamycin – 0.52 0.25
Bold letters are for the substituted amino acids, italicized for the unfavorable
substitution that are revert back to the parent amino acid and the bold and italized
represents the favorable substitution of the amino acid that are carry forwarded. The
ﬁnal peptide L10 contains all the possible favorable substitutions.
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The assessment of mitochondrial permeability was done by using
the ﬂuorescent probe rhodamine 123 (Sigma), since it accumulates in
the cell compartment [19]. Brieﬂy, the yeast cells in log phase were
suspended in potassium phosphate buffer (1 mM, pH 7.0) and incu-
bated with rhodamine 123 (5 μM) for 15 min at 37 °C in a water
bath. After 3 washes with potassium phosphate buffer, the cells
were treated with L10 at concentration two times their respective
MICs for 10 min at 37 °C. The distribution of rhodamine 123 in the
yeast cells was examined using a ﬂuorescence microscope (NIKON
Eclipse E600).
2.12. Anti-inﬂammatory assay
The inﬂammatory enzyme COX-2 used for binding assay with L10
by SPR and spectrophotometric methods.
2.12.1. SPR studies
The real time measurement of the interaction between COX-2 with
L10 was performed using a biosensor method based on SPR [30]. Six
Histidines-tags attached to the terminal position of COX-2 were ideal
for immobilization due to the strong rebinding effect caused by the
high surface density of immobilized Ni2+–Nitriloacetic acid (NTA) on
the chip. The binding of analyte, i.e., the peptide in solution, can be stud-
ied bymonitoring the change in the RUvalues of the sensorgram,where
the progress of the interaction is plotted against time, thus revealing the
binding characteristics. The parameters of binding kinetics, i.e., the equi-
librium association (KA) and equilibrium dissociation (KD) constant for
the formation ofmulti-molecular complex and dissociation,were deter-
mined in a very short time and with small amounts of samples. 60 μL of
His-tag COX-2 (50 μg/mL)was injected to one of the ﬂow cells at a ﬂow
rate of 5 μL/min. 900 RU of COX-2 were immobilized under these con-
ditions, where 1 RU corresponds to immobilized protein concentration
of ~1 pg mm2. The analyte, i.e., L10 (8.39 μM) was passed over the
immobilized COX-2 at a ﬂow rate of 10 μL/min for 4 min. Likewise,
two different concentrations 25.1 and 41.9 μM of L10 were passed
over the chip and the change in RU was observed. The constants KA
and KD were obtained from the primary sensogram data using the BIA
evaluation 3.0 software.
2.12.2. Inhibition studies of peptide
The COX-2 inhibitory property of the peptides was assayed. Initially,
the activity assay for the pure enzyme, COX-2 was performed in the
assay buffer (100 mM Tris-Cl; pH 8.0, 1 mM EDTA, 2 μM hematin) by
the addition of arachidonic acid (substrate) and N,N,N′,N′-tetramethyl
p-phenylenediamine (TMPD; co-substrate). TMPD oxidation was mon-
itored spectrophotometrically at 610 nm [31]. The inhibition by the
peptide was determined by pre-incubating it with enzyme in 1:1
molar ratio in the same conditions.
3. Results
3.1. Designing of peptide
Several studies have been conducted so far on the antimicrobial
properties of LF in order to map the different antimicrobial regions
of the LF molecule. In this study, we have focused on the role of the
shortest possible N-terminal antimicrobial domain of the bovine LF
prior to the disulphide bridge. The ﬁrst 8 N-terminal residues of bo-
vine LF, i.e., APRKNVRW (named as L1) were chosen as a template
for designing synthetic AMPs. Nine different peptides were designed
by changing the amino acids of L1 by incorporating the homologous
amino acid residues of different hydrophobicities by considering the
hydrophobic scale [32], and were studied for the antimicrobial activ-
ity against E. coli (ATCC 25923).We started the incorporation of the amino acids from the C-
terminal region of L1 and proceeded towards the N-terminal
(Table 1). In this respect, the ﬁrst amino acid at position one was W
in L1. Sticking to the hydrophobic scale and position speciﬁcity con-
cept, W was replaced by F in L2 (W and F belong to the same structur-
al class with different hydrophobicities). The MIC of L2 was found to
be more than L1. In L3, the second residue, R of L2 was substituted
by K. Similarly, L4 to L10 peptides were synthesized by replacement
of amino acid and MICs were determined. The sequence and the
activity data of all the peptides are provided in Table 1. Among all
the peptides, L10 was the best-designed peptide showing MIC of
1 μg/mL, so it was further tested for its other in vitro activities.
3.2. Antimicrobial activity
Table 2A reports the MICs for the L10 with different ESBL positive
bacterial strains cultured from different patient samples. The range
for the MIC was reported to be 1–8 μg/mL (with an average of
4.06 μg/mL for 30 clinically isolated strains). L10 was also found to
have promising antifungal activities. Table 2B shows the MICs for
different Candida strains, ATCC and clinical isolates. The peptide was
found to be most active against C. albicans (ATCC 4923) and
C. parapsilosis (ATCC 22019) with signiﬁcant MIC values.
3.3. Stability test
The stability of the peptide in the solution is one of the key factors
in determining its antimicrobial efﬁciency within a given period of
time. There was no detectable change in the antimicrobial activity
of the L10 even after 30 days of storage, as compared to a freshly
prepared solution (data not shown).
3.4. MHC measurements
The peptide was found to be nearly non hemolytic even at high con-
centrations. Less than 1.5% of 4% v/v hRBCwere hemolyzed by 800 μg/mL
of L10. Fig. 1 shows the hemolytic effect of L10. Gentamycin was used as
positive control.
3.5. Therapeutic index
The peptide was found to be non-hemolytic to the mammalian
erythrocyte at a concentration of 800 μg/mL, hence the TI value was
calculated from 1600 μg/mL. The higher values obtained for the pep-
tide reﬂect its being a highly speciﬁc AMP [32]. This factor indicates
the ability of the drug to selectively target the pathogen instead of
the patient's own cells.
Table 2A
Minimal inhibitory concentration (MIC), source of isolation and therapeutic index (TI) for the peptide L10 against different bacterial strains.
Sl No. Sample number/Patient ID Organism Cultured from MIC (μM) MIC (μg mL−1) Therapeutic Indexa
1 ATCC (25923) E. coli – 0.8 1 1600
2 309/19.3.10 K. pneumoniae Sputum 3.35 4 400
3 301/19.3.10 Acinetobacter sp. Sputum 1.67 2 800
4 302/19.3.10 Psudomonas aruginosa Sputum 6.71 8 200
5 305/19.3.10 K. pneumoniae Sputum 3.35 4 400
6 312/19.3.10 Acinetobacter sp. Sputum 3.35 4 400
7 224/18.3.10 K. pneumoniae Pus 3.35 4 400
8 217/19.3.10 E. coli Pus 1.67 2 800
9 202/19.3.10 K. pneumoniae Pus 6.71 8 200
10 237/19.3.10 E. coli Pus 0.8 1 1600
11 309/25.3.10 K. pneumoniae Sputum 3.35 4 400
12 301/25.3.10 Acinetobacter sp. Sputum 3.35 4 400
13 305/25.3.10 K. pneumoniae Sputum 3.35 4 400
14 312/25.3.10 Acinetobacter sp. Sputum 6.71 8 200
15 207/25.3.10 E. coli Pus 1.67 2 800
16 302/25.3.10 K. pneumoniae Sputum 6.71 8 200
17 287/25.3.10 E. coli Pus 3.35 4 400
18 322/25.3.10 Acinetobacter sp. Sputum 3.35 4 400
19 241/26.3.10 E. coli Pus 6.71 8 200
20 301/26.3.10 E. coli Sputum 3.35 4 400
21 35/26.3.10 E. coli Urine 6.71 8 200
22 330/26.3.10 K. pneumoniae Sputum 3.35 4 400
23 36/26.3.10 E. coli Urine 6.71 8 200
24 214/26.3.10 E. coli Pus 1.67 2 800
25 47/26.3.10 E. coli Urine 3.35 4 400
26 225/26.3.10 E. coli Pus 0.8 1 1600
27 322/19.3.10 E. coli Sputum 3.35 4 400
28 341/27.3.10 K. pneumoniae Sputum 1.67 2 800
29 43/27.3.10 E. coli Urine 3.35 4 400
30 241/27.3.10 K. pneumoniae Pus 3.35 4 400
31 291/27.3.10 E. coli Pus 1.67 2 800
a The therapeutic index is the ratio of MHC to MIC.
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As in many other AMPs, the bacterial killing by L10 is a very rapid
process. Its kinetic activity against the E. coli (ATCC 25923) was com-
plete after a mere 40 min exposure, at a concentration two times the
MIC. However, it showed slightly slower (60 min) killing activity in
ESBL positive E. coli isolated from patients. Fig. 2A shows the kinetics
results obtained from the standard strain E. coli (ATCC 25923) and
ESBL positive E. coli.
Similar rapid killing kinetics observed against fungi. C. albicans
(ATCC SC5314) and C. tropicalis (ATCC 13803), these being killed
within 140 min and 90 min exposure respectively, even at concentra-
tions twice their respective MICs (Fig. 2B).Table 2B
MIC and TI of the peptide L10 against different fungal strains.
Sl
no.
Sample number/
patient ID
Organism MIC
(μM)
MIC
(μg mL−1)
TI
1 ATCC SC5314 C. albicans 10.49 12.5 128
2 ATCC 13803 C. tropicalis 20.98 25 64
3 ATCC 6258 C. krusei 20.98 25 64
4 ATCC 15126 C. glabrata 20.98 25 64
5 ATCC 22019 C. parapsilosis 5.24 6.25 256
6 4762 C. albicans 83.93 100 16
7 4662 C. albicans Not active Not active Not determined
8 4615 C. albicans 41.96 50 32
9 4748 C. albicans 20.98 25 64
10 4923 C. albicans 5.24 6.25 256
11 5527 C. albicans 20.98 25 64
12 4912 C. tropicalis 10.49 12.5 128
13 4345 C. tropicalis 20.98 25 64
14 4913 C. tropicalis 20.98 25 64
15 5552 C. tropicalis 83.93 100 16
16 4739 C. glabrata Not active Not active Not determined3.7. Electron microscopic studies
To further characterize the bactericidal and fungicidal effects of
the peptides, we used TEM and SEM to examine ESBL positive E. coli
C. albicans (ATCC SC5314) and C. tropicalis (ATCC 13803), respective-
ly. We found that bacterial cells exposed to L10 at its MIC (4 μg/mL,
which is the average MIC obtained when all strains were taken into
account) showed altered cell membrane morphology, with the
appearances of membrane blisters. Since the kinetic experiments
revealed that longer duration of incubation of bacterial cells with
the peptide causes total lysis of the cells, the shorter duration effects
were analyzed after ﬁxing and sectioning (Fig. 3A).
At 5 min of incubation, changes like invagination in the cytoplasmic
membrane, blebbing and formation of vacuoles were observed. After
15 min, the majority of the cells displayed leakage of cytoplasm. At
30 min of incubation, a large amount of cell debris was present. More-
over, a number of the remaining cells appeared to have clumping orFig. 1. Hemolytic activity of L10onhumanRBCs. Each value shown is themean±standard
error of the mean from three experiments. Amp B is positive control.
Fig. 2. Killing kinetics by the peptide L10. (A) E. coli (ATCC 25923) and ESBL positive
E. coli, (B) C. albicans (ATCC SC5314) and C. tropicalis (ATCC 13803). Each value
shown is the mean±standard error of the mean from three experiments.
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ing. A similar kind of observationwas recordedwith the fungal cells' ar-
chitecture, as assessed by the SEM on the cell walls of C. albicans (ATCC
SC5314) and C. tropicalis (ATCC 13803), (Fig. 3B). The surface exposed
to the peptide gave the appearance of being perforated. They also
showed altered cell membrane morphology, leakages of cytoplasmic
contents and appearances of membrane blisters, along with deep pits.
3.8. Properties supporting the antibacterial activity
3.8.1. LPS binding activity
Using LAL assay kit, L10 was analyzed for its capacity to bind with
LPS. The binding of L10 to LPS was observed at low peptide concentra-
tions, completely neutralizing the LPS at 24 μg/mL (Fig. 4). The factor
has been related to the charges of AMPs. Since the L10 bears high
cationicity, the LPS binding activity is predominant.
3.8.2. Binding of LA with peptide L10
The sensorgram (Fig. 5) shows the binding of the varying concen-
trations of the L10. The changes in RU with varying concentrations
show the changes of mass on the LA immobilized on chips, over
time. The dissociation constant (KD) calculated by BIAevaluation soft-
ware 3.0 was 1.52×10−8 M.
3.9. Properties supporting the anticandidal activity
3.9.1. Candida membrane permeability
The percentage of PI-positive cells demonstrated the perme-
abilization of the cytoplasmic membrane induced by the peptidesafter 2 h of incubation with the respective fungal strains (Fig. 6A).
The percentage of PI-positive cells treated with L10 (1000 μg/mL)
for C. albicans (ATCC SC5314) and C. tropicalis (ATCC 13803) were
97% and 89%, respectively. However, at lower concentrations of the
peptide (10 μg/mL), there was indication of a high intake of dye.
The data obtained can be correlated with MIC values.
3.9.2. Candida mitochondrial membrane permeability
The effect of the peptides on mitochondrial membrane integrity
was studied by the mitochondrial ﬂuorescent probe rhodamine 123
(Fig. 6B). It was found to be localized to sub-cellular compartments,
presumed to be mitochondria, in the yeast cells. The typical granular
appearance is indicative of mitochondrial localization. 10 min of
exposure of the peptide L10 to C. albicans (ATCC SC5314) and
C. tropicalis (ATCC 13803) changed the pattern of ﬂuorescence in
the cell, showing a uniform distribution all over the cells.
3.10. Anti-inﬂammatory assay
3.10.1. SPR studies
The changes in RU obtained with varying concentrations of peptide
passed over immobilized inﬂammatory enzyme COX-2 on sensor chip
indicated the change in bound mass on sensor surface, over time.
Fig. 7A shows the sensogram of binding of three different concentra-
tions of L10. The dissociation constant KD was found to be 6.92 μM for
the peptide. This can be considered as a potent anti-inﬂammatory
peptide.
3.10.2. Inhibition studies of peptides with COX-2
The activity assay of COX-2 in the presence of the substrate
(arachidonic acid) and L10 was performed using UV spectrophotom-
eter. The activity proﬁle of COX-2 showed an increase in absorbance
with time, in presence of substrate (Fig. 7B). The rate of absorbance
became stable much earlier in the presence of the peptide, indicating
decline in the rate of activity of COX-2 an inhibition of 74%.
4. Discussion
The causes of the rapid emergence and dissemination of MDR
strains in hospitals are multifactorial. One of the most important fac-
tors is the selective pressure of antimicrobials commonly used in
treating hospitalized patients. Cross-transmission from patient to pa-
tient occurs owing to inconsistent application of appropriate infection
control measures, and the inter hospital transfer of resistance. These
factors lead to the development of the MDR strains. The most com-
mon pathogen, the E. coli responsible for bacterial infections in the
urinary tract, and pneumonia, has been now characterized under
the MDR strains.
The upcoming of ESBL producers has rendered the currently avail-
able antibiotics ineffective [33]. Similar is the status of the common
Candida infection in human blood stream, a life threatening invasive
disease causing signiﬁcant mortality and morbidity. According to an
Indian case report, the proportion of C. tropicalis was higher than
that observed in US and Europe [34]. Flucanazole is widely used for
treating fungal infections. Unfortunately, long term therapies have
led to the emergence of ﬂucanazole resistant C. albicans strains that
are cross resistant to other azoles and also to amphotericin B [35].
As a consequence, AMPs represent an elite new class of antimicro-
bials with the capability of tackling these issues. The advantages of
peptides as drugs include their high speciﬁcity, potency, and activity.
Small peptides, as drugs, are very speciﬁc in nature. Other advantages
over therapeutic proteins include higher solubility, better stability,
more bioavailability and negligible immune response. In the present
study, we have designed a peptide based on the N-terminal fragment
of the parent bovine LF molecule because of its practical implications
as regards many beneﬁcial physiological activities. This domain
Fig. 3. Ultrastructural changes in bacteria and fungi, treated with peptide. (A) Transmission electron micrographs (TEM) of control ESBL positive E. coli (C1), 5 min after incubation
with L10 (4 μg/mL) (T1), 15 min after incubation (T2) and 30 min after incubation (T3) (Scale: 200 nm in all images), (B) Scanning electron microscopy of C. albicans (ATCC
SC5314) and C. tropicalis (ATCC 13803) exposed to 25 μg/mL and 100 μg/mL of L10 or buffer alone (control) for 2 h (magniﬁcation ×5000).
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acid residues that are important for antimicrobial activity. The cation-
ic AMPs, derived from the N-terminal domain of the LF, have been
shown to kill sensitive microorganisms by inducing cell membrane
permeability, leading to the disruption of energy metabolism or
other essential functions in the target organism [12]. The isolated
peptides and the synthetic analogs of the identiﬁed peptide are
more effective than the native LF, suggesting that the smaller size
may facilitate access to target sites on the microbial surface [15,36].
This study revealed a short, potent AMP L10 which showed a
broad-spectrum of antimicrobial activity against a wide variety of
clinical isolates of ESBL producing gram-negative bacteria and MDR
resistant Candida sp. isolated from hospitalized patients. TheFig. 4. LPS-binding activity (%) of L10 peptide. LPS was incubated with different
concentrations of L10 and the binding was measured at 545 nm. Same concentrations
of colistin were used as a positive control.hemolytic studies showed that the peptide was almost non-toxic to
human erythrocytes. This aspect of the peptide L10 showed that it
can be administered by intravenous route. As both the values of MIC
and MHC were carried out by serial two-fold dilutions, the therapeu-
tic index could vary as much as four-fold for individual microorgan-
isms, when the peptide is both hemolytic and antimicrobial.
However, it may vary up to two-fold when the peptide is non hemo-
lytic. It is reported that the larger the value of TI, the greater is the an-
timicrobial speciﬁcity [32]. L10 possesses high microbial speciﬁcity
and was found to be highly stable in all conditions. The time-kill
assay highlighted the rapid rate of bacterial mortality after adminis-
tering this peptide. This property revealed that there are less chances
of microbes developing resistance to it. Such resistance against a par-
ticular antibiotic is often encountered in the case of bacteria
exhibiting a long annihilation time, thus giving strains enough time
to revert themselves. Since cationic AMPs exhibit a high afﬁnity for
LPS and lipoteichoicacid (LTA) [37–39], permeabilization and lysis of
microbes are the corollary.
LPS is one of the most powerful stimulants of the immune system
[40]. It activates toll like receptors on macrophages, monocytes
and neutrophils, which then release prototypic pro-inﬂammatory
cytokines like interleukin-1, interleukin-6 and tumor necrosis factor-
alpha. These cytokines trigger an inﬂammatory cascade. This may lead
to disseminated intravascular coagulation (mortality, 25–30%) as well
as vascular instability and capillary leak contributing to the hyperten-
sion seen in septic shock [41,42]. By binding and neutralizing LPS, it
would be possible to avoid these mechanisms, which contributes to
the pathophysiology of sepsis. The LPS binding assay showed its potent
and effective neutralization by L10. Further, it interacts with LA with a
KD value comparable to any of the known LA-peptide complexes
(Table 3).
Fig. 5. Sensogram showing binding of different concentrations of peptide L10 (I1=4.19 μM, I2=12.58 μM and I3=20.97 μM) on the LA immobilized surface over a HPA chip.
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volve an increase inmembrane potential and permeability [43,44] and
recently, the antimicrobial mechanism has been putatively associated
with conductive ATP transport [45,46]. TEM and SEM studies also indi-
cate that the peptide acts primarily on the cell membrane of E. coli and
Candida sp. by disrupting the cell wall and mitochondrial membrane.
The alteredmorphologies of the E. coli in TEM revealed the membrane
as the target of action. Further, the result of SEM study showed the loss
of fungal cytoplasmic contents by forming deep pits on the cell wall.
However, the exact mode of action of AMP can be multiple, but here,
the fast killing kinetics as well as the electron microscopy studies
suggested that the major cause of peptide antimicrobial action is itsFig. 6.Membrane permeabilization property of L10. (A) Propidium iodide (PI) staining and
37 °C with various concentrations (1, 10, 100 and 1000 μg/mL) of the peptide. Fluorescence
SC5314) and C. tropicalis (ATCC 13803). Brieﬂy, cells pre loaded with rhodamine 123 for 10
after addition, (b) or after a 10 min incubation with the peptide (magniﬁcation ×100).membrane interactive nature. The effect of peptides from human LF
on the cell surface of C. albicans as well as the membrane perme-
abilization activity has also been reported earlier [47,48].
Some AMPs appear to be antifungal molecules by virtue of their
propensity to rupture the fungal membrane and suppress mitochon-
drial respiration [49]. The peptide also targets the mitochondria of
the Candida as expressed by rhodamine 123, while the action of the
ﬂuorescence dye on the conﬁned mitochondria indicated that the
peptide accumulated in the cytoplasm. The permeabilization of cyto-
plasmic membrane was also conﬁrmed by peptide stimulated PI pos-
itive fungal cells. In addition, L10 seems to be a potent competitive
COX-2 inhibitory molecule. The binding afﬁnity of L10 with COX-2killing of C. albicans (ATCC SC5314) and C. tropicalis (ATCC 13803) incubated for 2 h at
microscopy studies of L10, (B) treatment of rhodamine 123-labeled C. albicans (ATCC
min at 37 °C were washed and treated with L10. (a) Pictures were made immediately
Fig. 7. COX-2 binding and inhibition by the peptide L10. Sensogram showing binding of
different concentrations of peptide, (A) L10 (I1=8.39 μM, I2=25.1 μM and I3=
41.9 μM) on the Ni+2 NTA chip immobilized with His-COX-2. Inhibition kinetics
assay of L10, (B) Activity proﬁle of pure COX-2 alone and incubated with L10 in 1:1
molar for 45 min at room temperature. Each value shown is the mean±standard
error of the mean from three experiments.
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analysis. This aspect of the peptide showed that it may exhibit
anti-inﬂammatory property.5. Conclusion
It can be concluded that L10 can be considered a potential
therapeutic candidate against infections caused by ESBL positive
E. coli, K. pneumonia, Acinetobactor sp. and Candida sp. due to its
high antibacterial, antifungal, anti hemolytic, anti-inﬂammatory and
antiendotoxin activities. Hence, it is a multifunctional molecule that
may open up an alternative approach to the critical task of developing
novel anti microbial agents, in view of the increasing problem of mi-
crobial resistance to conventional therapies.Acknowledgements
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